DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market

DexCom, Inc. (NASDAQ: DXCM) has reported CONNECT randomized controlled trial results showing that Dexcom G7 continuous glucose monitoring improved A1C and glucose control in adults with Type 2 diabetes who were not using insulin. The study matters strategically because DexCom, Inc. is trying to move continuous glucose monitoring deeper into mainstream Type 2 diabetes care, not just the insulin-using population where the category has already gained stronger clinical and reimbursement acceptance. The data give DexCom, Inc. a stronger evidence base for payers, clinicians and primary care networks at a time when digital diabetes management is becoming more closely linked with GLP-1 therapies, SGLT2 drugs and broader metabolic health programs. DXCM last traded at $72.86, modestly lower over the latest five-session window but sharply higher over the prior month, placing the stock between its 52-week low of $54.11 and 52-week high of $89.98 as investors reassess the company’s growth runway.

Why could DexCom CONNECT study results expand the addressable market for continuous glucose monitoring?

The most important element of the CONNECT study is not merely that Dexcom G7 improved glucose metrics. The commercial significance lies in the patient population. DexCom, Inc. has already built its core business around people with diabetes who require intensive monitoring, particularly those using insulin, but Type 2 diabetes patients not using insulin represent a far wider and historically harder-to-penetrate opportunity. That group has often been managed through periodic A1C tests, lifestyle interventions, oral medication and intermittent finger-stick testing rather than continuous data.

CONNECT gives DexCom, Inc. a more formal argument that continuous glucose monitoring can produce measurable benefit even when insulin titration is not the central clinical issue. In the study, adults using Dexcom G7 saw an average 1.6 percentage point A1C reduction from a baseline mean A1C of 8.8%, with a 0.9 percentage point greater reduction than the routine care control group. For participants with an initial A1C above 10%, the average A1C reduction was 3.1%, which points to a potentially stronger role for continuous glucose monitoring in patients with poorer baseline control.

The competitive implication is clear. DexCom, Inc. is not simply defending its existing market against Abbott Laboratories, Medtronic plc and other diabetes technology competitors. It is trying to expand the definition of who should use continuous glucose monitoring in the first place. If clinicians and insurers accept that CGM can influence behaviour, medication adherence, diet choices and disease awareness among non-insulin Type 2 diabetes patients, the market shifts from a device category for high-intensity diabetes management to a broader metabolic monitoring category.

How does Dexcom G7 clinical evidence change the commercial case in non-insulin Type 2 diabetes?

Dexcom G7’s performance in CONNECT strengthens the argument that real-time feedback can change outcomes without requiring the user to be on insulin. That distinction matters because payers have historically been more willing to reimburse continuous glucose monitoring when the clinical need is obvious, such as avoiding hypoglycemia in insulin users. Non-insulin Type 2 diabetes is more complicated from a reimbursement standpoint because the device must prove that it changes behaviour and reduces risk, not merely that it produces useful data.

The study reported that 82% of participants using Dexcom G7 achieved at least a 0.5 percentage point A1C reduction. It also showed that 68% of Dexcom G7 users reached A1C below 7.5% after 26 weeks, while 46% reached A1C below 7.0%. Those endpoints are commercially useful because they translate clinical performance into numbers that primary care physicians, benefit managers and employers can understand. In a reimbursement conversation, “better visibility” is nice, but “more patients reached glycemic targets” is much harder to wave away.

The data also position Dexcom G7 as a companion technology for existing diabetes drug regimens rather than a substitute for them. CONNECT showed additive A1C reductions across medication groups, including participants using metformin, GLP-1 therapies and SGLT2 inhibitors. That is strategically important because the rise of GLP-1 drugs has changed the diabetes and obesity care conversation. DexCom, Inc. can argue that continuous glucose monitoring helps patients and clinicians understand how medication, diet and lifestyle interact in real time. In other words, the sensor does not need to compete with the prescription pad. It can make the prescription pad smarter.

Why does non-insulin Type 2 diabetes matter for DexCom, Abbott Laboratories and digital health competitors?

The non-insulin Type 2 diabetes market matters because it sits at the intersection of chronic disease management, preventive care, employer health spending and consumer health behaviour. DexCom, Inc. has already moved beyond traditional diabetes hardware through Stelo, its over-the-counter biosensor platform aimed at adults not using insulin. CONNECT adds clinical weight to that broader strategy by showing that CGM can deliver measurable outcomes in a medically supervised, randomized setting.

For Abbott Laboratories, which has built major global scale through FreeStyle Libre, the study raises the competitive stakes in a market where access, pricing, sensor duration, app experience and payer acceptance will all matter. Abbott Laboratories has often competed strongly on scale and affordability, while DexCom, Inc. has leaned heavily on accuracy, connectivity and premium clinical positioning. If non-insulin Type 2 diabetes becomes the next major battleground, the contest will not be won by sensor hardware alone. It will be won through evidence, reimbursement strategy, pharmacy access, software integration and clinician workflow.

Digital health companies are also watching this space because CGM data can feed nutrition coaching, remote monitoring, employer wellness programs and cardiometabolic risk platforms. That creates a second-order risk for DexCom, Inc. The company may benefit from broader CGM adoption, but it must also defend the patient relationship as diabetes care becomes more app-driven and partner-heavy. The sensor may be the data source, but the company that owns the daily user habit could capture a meaningful share of long-term value.

How does DexCom stock performance reflect investor caution despite stronger clinical evidence?

DXCM’s market reaction needs to be read with some restraint. The stock closed at $72.86 in the latest available trading session, up 0.37% on the day. Over the latest five-session window from the May 29 close to the June 5 close, the stock slipped by about 1.2%, suggesting the CONNECT data had not yet triggered a decisive short-term re-rating. Over the roughly one-month window from the May 6 close, however, DXCM rose by about 20.7%, showing that investors had already been rebuilding confidence before the CONNECT announcement.

That mixed picture is rational rather than disappointing. Clinical data can strengthen a long-term thesis, but investors still need proof that evidence converts into coverage decisions, prescription growth, sensor utilization and margin discipline. DexCom, Inc. already trades with a growth-stock premium relative to many traditional medical device companies, so the market is unlikely to reward every positive clinical readout unless it sees a credible path to revenue acceleration.

The latest financial backdrop gives DexCom, Inc. room to press the opportunity. The company reported first-quarter 2026 revenue of $1.192 billion, up 15% year over year, with United States revenue up 11% and international revenue up 26% on a reported basis. DexCom, Inc. also guided for 2026 revenue of $5.16 billion to $5.25 billion, implying growth of about 11% to 13%. With $2.42 billion in cash, cash equivalents and marketable securities at the end of the first quarter, the company has balance-sheet flexibility to support commercialization, evidence generation and manufacturing capacity. The market’s caution, therefore, appears less about whether DexCom, Inc. has a viable business and more about whether the next growth leg can be scaled efficiently.

What execution risks could slow DexCom’s push from insulin users into mainstream diabetes care?

The biggest risk is not that CGM lacks usefulness for non-insulin Type 2 diabetes. The risk is that usefulness alone does not guarantee broad adoption. Primary care physicians are already managing heavy patient loads, and a flood of glucose data can become a workflow burden unless it is presented in a practical way. DexCom, Inc. must ensure that its software turns CGM readings into clear intervention points rather than another dashboard that clinicians politely ignore while drinking cold coffee between appointments.

Payer adoption is another major swing factor. Insurers and pharmacy benefit managers may ask whether continuous glucose monitoring should be reimbursed continuously for all non-insulin Type 2 diabetes patients, used intermittently for behaviour change, or targeted only to higher-risk patients with poor control. CONNECT strengthens the case for broader use, but payer policy often moves slowly, particularly when the budget impact of category expansion could be large. DexCom, Inc. may need additional real-world evidence showing reduced complications, fewer medication escalations, better adherence or lower long-term cost.

Pricing and channel design will also be decisive. If DexCom, Inc. pushes too hard on premium positioning, Abbott Laboratories and other competitors may use affordability as a wedge. If DexCom, Inc. leans too aggressively into consumer-style access, it risks confusing the distinction between medical CGM, wellness tracking and prescription-supported diabetes management. The company has to thread the needle between medical evidence and consumer convenience. That is a good problem to have, but it is still a problem.

Why could payer behaviour determine whether CONNECT becomes a growth catalyst for DexCom?

CONNECT is best understood as a payer-facing asset as much as a clinical study. For DexCom, Inc., the commercial prize is not simply convincing more patients that continuous glucose monitoring is useful. The prize is persuading healthcare systems that CGM should be embedded earlier in Type 2 diabetes management. That requires evidence that the device can improve outcomes across demographics, medication regimens and insurance categories.

The study’s design helps because it involved 22 primary care practices across the United States, screened 440 participants, randomized 283 eligible adults and analyzed key outcomes from 265 participants who completed the 26-week study. Primary care relevance is important because many non-insulin Type 2 diabetes patients are not managed in specialist endocrinology settings. If continuous glucose monitoring requires specialist-heavy interpretation, adoption will be slower. If it can fit primary care and pharmacy-led models, the addressable market expands meaningfully.

The next stage will likely depend on sustainability and economics. A six-month extension phase is expected to provide data up to 12 months, which could become important for insurers deciding whether CGM benefits persist or fade after the novelty effect wears off. Investors should watch whether future data support durable behaviour change, high sensor engagement and consistent improvement across medication subgroups. A strong 26-week result opens the door, but sustained 12-month evidence is what could help keep payers in the room.

What does the DexCom CONNECT study signal about the future of diabetes technology?

The broader industry signal is that diabetes technology is moving from reactive monitoring toward continuous metabolic intelligence. The old model measured glucose periodically and adjusted treatment after the fact. The emerging model gives patients and clinicians a live feedback loop, linking food, exercise, stress, sleep, medication and glucose response. DexCom, Inc. wants to be central to that loop.

This shift matters because the diabetes market is being reshaped from multiple directions at once. GLP-1 therapies are changing weight and glucose management. SGLT2 drugs have expanded cardiometabolic and kidney-related treatment logic. Remote monitoring is becoming more accepted by health systems. Employers and insurers are looking for chronic disease tools that can demonstrate measurable outcomes. CGM sits neatly inside that convergence, provided it can prove that more data leads to better decisions rather than just prettier charts.

For DexCom, Inc., CONNECT is therefore more than a clinical milestone. It is a strategic bridge between the company’s established medical device franchise and a broader metabolic health platform. The opportunity is large, but the burden of proof rises as the company moves from high-need insulin users into earlier-stage Type 2 diabetes. The next challenge is not proving that Dexcom G7 works in a trial. It is proving that DexCom, Inc. can convert trial credibility into payer policy, clinician adoption and durable revenue growth without letting competitive pressure squeeze the economics.

Key takeaways on what DexCom CONNECT study means for CGM adoption, competitors and investors

• DexCom, Inc. has strengthened its clinical case for using Dexcom G7 in adults with Type 2 diabetes who are not using insulin, a population that could materially expand the company’s addressable market beyond its traditional insulin-focused base.
• CONNECT gives DexCom, Inc. a more credible reimbursement argument because the study showed A1C improvement, better time in range and strong user engagement rather than relying only on the general appeal of real-time glucose visibility.
• The study’s primary care setting matters because non-insulin Type 2 diabetes patients are often managed outside specialist endocrinology channels, making workflow simplicity a key factor in whether CGM adoption can scale.
• DexCom, Inc. may benefit from the rise of GLP-1 and SGLT2 therapies because CGM can help patients and clinicians understand how medication, diet and lifestyle affect glucose patterns in real time.
• Abbott Laboratories, Medtronic plc and other diabetes technology competitors are likely to face a more evidence-driven race in non-insulin Type 2 diabetes, where pricing, access and software usability could matter as much as sensor performance.
• DXCM’s recent stock movement suggests investors are interested but not euphoric, with the share price higher over the prior month but not decisively re-rated after the CONNECT study announcement.
• DexCom, Inc.’s first-quarter revenue growth and cash position give the company flexibility to invest behind commercialization, but broader CGM adoption will still depend on payer coverage and channel execution.
• The biggest commercial risk is that insurers may choose targeted or intermittent CGM coverage for non-insulin Type 2 diabetes rather than broad continuous reimbursement for all eligible patients.
• The six-month extension phase of CONNECT could become important because longer-duration evidence may help determine whether early improvements persist and whether payers view CGM as a durable intervention.
• The strategic question for DexCom, Inc. is shifting from whether CGM can improve diabetes monitoring to whether the company can turn continuous glucose data into a mainstream metabolic health platform.